PolyPid Announces Conference Call for D-PLEX100 Trial Results
PolyPid Ltd. (NASDAQ: PYPD), based in Israel, is gearing up to share significant advancements in surgical therapeutics. They have scheduled a conference call to discuss the topline results from the SHIELD II Phase 3 trial, focusing on their innovative drug, D-PLEX100. This drug aims to prevent surgical site infections that can arise in patients undergoing abdominal colorectal surgeries.
Details of the Conference Call
Date and Time
The conference call will take place on a Monday morning at 8:30 a.m. Eastern Time. It's encouraged for listeners to register at least five minutes prior to ensure a seamless connection.
How to Participate
Participants can join the call through a dedicated link that provides access to both the conference and the accompanying webcast. This session will be vital for anyone interested in the ongoing innovations within PolyPid and how D-PLEX100 could impact surgical practices.
Understanding D-PLEX100 and Its Impact
D-PLEX100 is a specialized therapeutic designed for extended release following surgery. Its innovative formulation utilizes PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, aiming to deliver medication directly where it is most needed. This method not only ensures controlled medication delivery over an extended period but promises to significantly reduce the occurrence of postoperative infections.
PolyPid’s Ongoing Commitment to Surgical Outcomes
As a late-stage biopharmaceutical company, PolyPid is focused on improving surgical outcomes through tailored therapeutic solutions. The Phase 3 clinical trial is a critical step in validating the efficacy of D-PLEX100 in real-world surgical settings. Furthermore, PolyPid is actively working on other projects, including OncoPLEX, which targets solid tumors and is currently in preclinical testing. Such advancements indicate PolyPid's robust pipeline aimed at addressing significant medical needs.
Further Information and Updates
For more information about PolyPid and their upcoming innovations, interested parties are invited to visit their official website. Ongoing updates will also be shared through their social media channels, including Twitter and LinkedIn. Engaging with these platforms can provide insights into future developments and community engagements.
Contacts for Inquiries
Those seeking more details regarding the conference call or PolyPid's initiatives can reach out directly to Ori Warshavsky, COO – US, at 908-858-5995, or you can send inquiries via email to IR@Polypid.com.
Frequently Asked Questions
What is D-PLEX100?
D-PLEX100 is a therapeutic product from PolyPid designed to prevent surgical site infections following abdominal colorectal surgeries.
When will the conference call occur?
The conference call will be held on a Monday morning at 8:30 a.m. Eastern Time.
How can one participate in the conference call?
Participants should register at least five minutes before the call through the provided registration link to ensure connectivity.
What technology does D-PLEX100 utilize?
D-PLEX100 employs PolyPid's proprietary PLEX technology for controlled release of medication, promoting effective prevention of infections.
Who can I contact for more information?
You can contact Ori Warshavsky at 908-858-5995 or email inquiries to IR@Polypid.com.
